NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.co ...

CLASS PERIOD: April 29, 2025 to June 23, 2025 NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submiss ...

Core Viewpoint - Hims & Hers Health is experiencing significant revenue growth and expanding its subscriber base, despite volatility in its stock price and challenges in the weight loss segment [1][4][6]. Financial Performance - In Q2, Hims & Hers reported a revenue increase of 73% year-over-year, reaching $544.8 million, which was at the high end of its forecast but below analyst expectations [4][10]. - Monthly online revenue per subscriber rose by 30% to $74, and the total number of subscribers increased by 31% to nearly 2.44 million [4][10]. - Adjusted EBITDA surged to $82.2 million, a 109% increase from the previous year, and adjusted EPS was $0.17, exceeding analyst expectations [8][10]. Subscriber Growth - The number of customers using at least one personalized subscription grew by 89% to 1.5 million, making up over 60% of the subscriber base [5]. - The company noted a 170% increase in subscribers using personalized treatment plans for multiple conditions, reaching over 500,000 [5]. Marketing and Expenses - Marketing expenses increased by 50% to nearly $218 million, accounting for 40% of revenue, down from 46% a year ago, indicating improved efficiency [7][10]. - The gross margin was reported at 76%, reflecting a decrease of 500 basis points year-over-year [10]. Future Outlook - Hims & Hers maintains its 2025 revenue forecast of $2.3 billion to $2.4 billion, representing growth of 56% to 63%, and adjusted EBITDA guidance of $295 million to $335 million [10][11]. - For Q3, the company projects revenue between $570 million and $590 million, with adjusted EBITDA of $60 million to $70 million [11]. - The company is planning international expansion, starting with Canada and targeting Europe, Latin America, and Asia in the coming years [11][12]. Growth Opportunities - Hims & Hers is expanding into new areas, including hormonal health, which is expected to contribute to its long-term revenue goals of $6.5 billion by 2030 [12]. - The company continues to see strong growth across various health categories, despite challenges in the weight loss segment [13]. Valuation - The stock trades at a forward P/E ratio of around 55 based on 2025 analyst estimates, with a PEG ratio under 0.6, indicating potential undervaluation [14]. - The price-to-sales multiple is 5.5 times 2025 estimates, suggesting reasonable pricing given the high gross margins of the subscription business [14].

Core Insights - Hims & Hers is experiencing rapid revenue growth but is currently facing a legal battle that poses risks to its future performance [1][4] - The company's stock has seen a significant decline of 17% this week and is down 25% from its all-time highs, despite a remarkable 400% increase over the past five years [1][2] Financial Performance - In Q2 2025, Hims & Hers reported a 73% year-over-year revenue growth, exceeding $500 million, driven by a 30% increase in total subscribers and a 30% rise in spending per active subscriber [2] - The company has achieved $2 billion in trailing revenue, marking an increase of over 1,000% in the last five years, solidifying its position as a leading telehealth provider [6] Legal Challenges - Hims & Hers is embroiled in a legal dispute with Novo Nordisk, stemming from allegations of selling knockoff weight loss drugs after a partnership ended due to disagreements [3][4] - The company is accused of illegally selling patented weight loss drugs at a discount now that the shortage has resolved, raising concerns among investors about the potential impact on future revenue and profitability [3][4] Market Position - Hims & Hers has made significant market share gains in the telehealth sector, particularly in the online provision of drugs and medical treatments [6] - Despite its strong growth trajectory, the ongoing legal issues may deter potential investors from buying the stock at its current dip [7][8]

Core Viewpoint - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud that affected investors between April 29, 2025, and June 23, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2]. - It is alleged that this situation created a substantial risk of termination of the Company's collaboration with Novo Nordisk [2]. - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - The complaint against Hims alleges violations of federal securities laws due to misleading statements and failure to disclose risks related to the sale of illegitimate drugs, leading to a significant drop in stock price following the termination of its partnership with Novo Nordisk [2][3]. Group 1: Allegations and Legal Actions - Hims is accused of engaging in deceptive promotion and selling of illegitimate versions of Wegovy®, which jeopardized patient safety [2]. - The termination of the partnership with Novo Nordisk was attributed to Hims' failure to comply with legal standards regarding drug sales and marketing practices [3]. - Following the announcement of the partnership termination, Hims' stock price plummeted by $22.24, or 34.6%, closing at $41.98 per share [3]. Group 2: Class Action Details - The lead plaintiff in the class action is the investor with the largest financial interest, who will oversee the litigation on behalf of the class [4]. - Any member of the putative class has the option to move the Court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [4]. Group 3: Call for Information - The law firm Faruqi & Faruqi encourages individuals with information regarding Hims' conduct, including whistleblowers and former employees, to come forward [5].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, which has led to a significant drop in its stock price following the termination of its partnership with Novo Nordisk [1][3]. Group 1: Lawsuit Details - The class action lawsuit is titled Sookdeo v. Hims & Hers Health, Inc. and covers the period from April 29, 2025, to June 23, 2025 [1]. - The lawsuit alleges that Hims & Hers made false statements and failed to disclose risks associated with its collaboration with Novo Nordisk, particularly regarding patient safety [2]. - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing deceptive practices, which resulted in a more than 34% decline in Hims & Hers stock price [3]. Group 2: Lead Plaintiff Process - Investors who purchased Hims & Hers securities during the class period can seek appointment as lead plaintiff, representing the interests of the class [4]. - The lead plaintiff is typically the investor with the greatest financial interest and must be typical and adequate of the class [4]. Group 3: Company Background - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [5].

Core Insights - Hims & Hers Health's stock has increased by approximately 24% since the last coverage, indicating positive market sentiment towards the company [1] - Following the announcement of the company's Q2'25 earnings report, there was a pre-market stock price drop, suggesting potential concerns among investors regarding the earnings results [1] Financial Performance - The Q2'25 earnings report is a significant event that has impacted the stock price, highlighting the importance of earnings announcements in influencing investor behavior [1] Market Sentiment - The surge in stock price prior to the earnings report reflects a bullish sentiment in the market, while the subsequent drop indicates a shift in investor confidence post-announcement [1]

LifeMD (LFMD -4.13%), a telehealth platform specializing in virtual care and digital health subscriptions, reported its second quarter 2025 financial results on August 5, 2025. Revenue (GAAP) was $62.2 million, up 23% from the same period last year but $4.1 million below consensus estimates (GAAP). Earnings per share (EPS) came in at a loss of $0.06 (GAAP), which was also below analyst expectations by $0.0517 (GAAP). Despite year-over-year expansion in core business metrics, results missed both revenue and ...

Company Overview - LifeMD is building a leading platform for comprehensive virtual healthcare[7] - The company has conducted 13 million virtual consults and has 297000 active patients[8] - LifeMD's revenue guidance for 2025 is between $250 million and $255 million[8] - The company has over 300 employees across the US[8] Investment Highlights - LifeMD forecasts $27 million to $29 million of Adjusted EBITDA for 2025[12] - The company's products and services generate 85%+ consolidated gross margins[12] - WorkSimpli, in which LifeMD holds a 73% equity stake, provides high-margin recurring revenue[9, 12] Financial Performance and Guidance - LifeMD forecasts 20% revenue growth in 2025, with revenue reaching $255 million[42] - Telehealth revenue is projected to grow by 23% to 27%, reaching $195 million to $200 million in 2025[50] - WorkSimpli is expected to generate $55 million in revenue in 2025, a 2% increase[50] - Consolidated Adjusted EBITDA is projected to increase by 93% to 107%, reaching $27 million to $29 million in 2025[50]